Currently out of the existing stock ratings of Matthew Andrews, 23 are a BUY (92%), 2 are a HOLD (8%).

Matthew Andrews

Work Performance Price Targets & Ratings Chart

Analyst Matthew Andrews, currently employed carries an average stock price target met ratio of 63.89% that have a potential upside of 31.98% achieved within 136 days. Previously, Matthew Andrews worked at JEFFERIES.

Matthew Andrews’s has documented 51 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SPPI, Spectrum Pharmaceuticals at 06-Sep-2018.

Wall Street Analyst Matthew Andrews

Analyst best performing recommendations are on SPPI (SPECTRUM PHARMACEUTICALS).
The best stock recommendation documented was for SPPI (SPECTRUM PHARMACEUTICALS) at 9/25/2017. The price target of $13 was fulfilled within 3 days with a profit of $3.16 (32.11%) receiving and performance score of 107.05.

Average potential price target upside

GEMP Gemphire Therapeutics IMMU Immunomedics NRBO Neurobo Pharmaceuticals TXMD TherapeuticsMD SPPI Spectrum Pharmaceuticals VNDA Vanda Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$2

$-5.5 (-73.33%)

$18

6 years 3 months 8 days ago
(13-Aug-2018)

3/4 (75%)

$0.34 (20.48%)

130

Hold

$2

$-5.5 (-73.33%)

$30

6 years 3 months 11 days ago
(10-Aug-2018)

1/3 (33.33%)

$14.2 (165.52%)

27

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Matthew Andrews?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?